The Role of Obesity in Cardiomyopathy and Nephropathy

E-ISSN： 1873-4286|20|9|1409-1417

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.20, Iss.9, 2014-03, pp. : 1409-1417

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Role of AGEs in Diabetic Nephropathy

Current Pharmaceutical Design, Vol. 14, Iss. 10, 2008-04 ,pp. : 946-952

Bentham Science Publishers

Access to resources Recommend Favorite

The Role of Sulodexide in the Treatment of Diabetic Nephropathy

By Weiss Ram

Drugs, Vol. 67, Iss. 18, 2007-01 ,pp. : 2681-2696

Adis International

Access to resources Recommend Favorite

A role for superoxide in gentamicin-mediated nephropathy in rats

By Cuzzocrea S. Mazzon E. Dugo L. Serraino I. Di Paola R. Britti D. De Sarro A. Pierpaoli S. Caputi A.P. Masini E. Salvemini D.

European Journal of Pharmacology, Vol. 450, Iss. 1, 2002-08 ,pp. : 67-76

Elsevier

Access to resources Recommend Favorite

Editorial [Hot Topic: Pathogenesis and Treatment of Diabetic Complications,Retinopathy, Nephropathy and Cardiomyopathy (Executive Editor: J.L. Wilkinson-Berka)]

Current Pharmaceutical Design, Vol. 13, Iss. 26, 2007-09 ,pp. : 2698-2698

Bentham Science Publishers

Access to resources Recommend Favorite

The Role of Angiotensin in Obesity and Metabolic Disease

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol. 11, Iss. 3, 2011-09 ,pp. : 198-205

Bentham Science Publishers

Access to resources Recommend Favorite